Vimta Labs Ltd
Vimta Labs Limited is testing food and drugs. It also does contract research for clinical research and pre-clinical studies provider in India. It provides analytical, clinical and preclinical services to life sciences industries; quality and safety testing for food and beverage industries; and environment services to a wide spectrum of industries. [1][2]
- Market Cap ₹ 1,154 Cr.
- Current Price ₹ 520
- High / Low ₹ 623 / 385
- Stock P/E 30.0
- Book Value ₹ 143
- Dividend Yield 0.38 %
- ROCE 16.8 %
- ROE 12.9 %
- Face Value ₹ 2.00
Pros
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 8.03% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
109 | 127 | 116 | 138 | 154 | 183 | 213 | 181 | 209 | 276 | 315 | 313 | |
88 | 101 | 99 | 119 | 127 | 138 | 155 | 151 | 156 | 196 | 222 | 229 | |
Operating Profit | 21 | 26 | 17 | 19 | 27 | 45 | 58 | 30 | 53 | 80 | 94 | 84 |
OPM % | 19% | 20% | 15% | 14% | 18% | 25% | 27% | 17% | 25% | 29% | 30% | 27% |
1 | 3 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 0 | 3 | 4 | |
Interest | 3 | 2 | 1 | 1 | 2 | 5 | 5 | 4 | 2 | 2 | 3 | 2 |
Depreciation | 15 | 9 | 11 | 10 | 10 | 16 | 20 | 21 | 23 | 23 | 31 | 34 |
Profit before tax | 4 | 18 | 7 | 8 | 17 | 26 | 35 | 8 | 28 | 55 | 64 | 52 |
Tax % | 4% | 25% | 24% | 23% | 36% | 36% | 28% | 17% | 25% | 26% | 26% | 25% |
4 | 13 | 5 | 6 | 11 | 16 | 25 | 7 | 21 | 41 | 47 | 39 | |
EPS in Rs | 1.90 | 5.99 | 2.29 | 2.91 | 4.79 | 7.43 | 11.45 | 3.13 | 9.62 | 18.57 | 21.37 | 17.51 |
Dividend Payout % | 32% | 33% | 44% | 34% | 0% | 27% | 17% | 0% | 21% | 11% | 9% | 11% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 8% |
3 Years: | 14% |
TTM: | -1% |
Compounded Profit Growth | |
---|---|
10 Years: | 11% |
5 Years: | 9% |
3 Years: | 22% |
TTM: | -18% |
Stock Price CAGR | |
---|---|
10 Years: | 16% |
5 Years: | 24% |
3 Years: | 25% |
1 Year: | 29% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 14% |
3 Years: | 17% |
Last Year: | 13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
Reserves | 108 | 116 | 118 | 122 | 132 | 148 | 167 | 169 | 190 | 229 | 276 | 312 |
12 | 7 | 4 | 26 | 44 | 40 | 26 | 32 | 30 | 19 | 15 | 19 | |
21 | 22 | 21 | 23 | 42 | 40 | 40 | 39 | 49 | 54 | 65 | 61 | |
Total Liabilities | 145 | 149 | 146 | 176 | 222 | 232 | 237 | 245 | 273 | 306 | 360 | 396 |
93 | 90 | 88 | 88 | 88 | 140 | 135 | 131 | 128 | 162 | 168 | 163 | |
CWIP | 0 | 2 | 0 | 6 | 53 | 0 | 4 | 2 | 17 | 0 | 12 | 59 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 6 | 6 | 6 |
51 | 57 | 58 | 82 | 80 | 92 | 99 | 105 | 122 | 138 | 174 | 168 | |
Total Assets | 145 | 149 | 146 | 176 | 222 | 232 | 237 | 245 | 273 | 306 | 360 | 396 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
16 | 17 | 15 | -1 | 24 | 33 | 39 | 24 | 37 | 59 | 87 | 59 | |
-4 | -8 | -8 | -16 | -39 | -24 | -16 | -20 | -32 | -38 | -57 | -75 | |
-11 | -8 | -9 | 19 | 13 | -8 | -23 | -1 | -5 | -16 | -11 | -2 | |
Net Cash Flow | 1 | 0 | -1 | 2 | -2 | 1 | 1 | 3 | 1 | 5 | 19 | -17 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 87 | 81 | 82 | 100 | 101 | 111 | 100 | 117 | 128 | 102 | 93 | 101 |
Inventory Days | 165 | 175 | 158 | 213 | 183 | 209 | 199 | 191 | 140 | 115 | 187 | 185 |
Days Payable | 147 | 87 | 66 | 77 | 184 | 148 | 115 | 114 | 139 | 81 | 119 | 61 |
Cash Conversion Cycle | 105 | 169 | 174 | 236 | 100 | 172 | 184 | 194 | 128 | 136 | 160 | 224 |
Working Capital Days | 88 | 84 | 120 | 126 | 68 | 88 | 87 | 100 | 116 | 96 | 84 | 102 |
ROCE % | 6% | 16% | 6% | 7% | 11% | 17% | 21% | 6% | 14% | 24% | 24% | 17% |
Documents
Announcements
- Closure of Trading Window 29 Jun
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
24 Jun - Notice of 34th AGM of the Company to be held on Thursday, 18th July, 2024 at 10:00 A.M.
- Reg. 34 (1) Annual Report. 24 Jun
- Announcement under Regulation 30 (LODR)-Date of payment of Dividend 24 Jun
- Book Closure From Friday, 12Th July 2024 To Thursday, 18Th July 2024 (Both Days Inclusive) For The Purpose Of Dividend &AGM. 24 Jun
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
May 2022TranscriptPPT
-
Oct 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Jan 2021TranscriptPPT
-
Oct 2020TranscriptPPT
-
Jun 2020TranscriptPPT
-
Feb 2020TranscriptPPT
-
Nov 2019TranscriptPPT
Services
The company deals in drug life cycle management, development and discovery support services, clinical research, central lab, and cGMP analytical services for pharmaceutical and biopharmaceutical companies.
It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters & regulators, and EMI/EMC testing for electronic and electrical products. [1]